Your browser doesn't support javascript.
loading
Single response assessment of transplant-ineligible multiple myeloma: a supplementary analysis of JCOG1105 (JCOG1105S1).
Nakamura, Nobuhiko; Maruyama, Dai; Machida, Ryunosuke; Ichinohe, Tatsuo; Takayama, Nobuyuki; Ohba, Rie; Ohmachi, Ken; Imaizumi, Yoshitaka; Tokunaga, Masahito; Katsuya, Hiroo; Yoshida, Isao; Sunami, Kazutaka; Kurosawa, Mitsutoshi; Kubota, Nobuko; Morimoto, Hiroaki; Kobayashi, Miki; Kato, Harumi; Kameoka, Yoshihiro; Kagami, Yoshitoyo; Kizaki, Masahiro; Takeuchi, Kazuto; Munakata, Wataru; Iida, Shinsuke; Nagai, Hirokazu.
Afiliação
  • Nakamura N; Department of Hematology and Infectious Disease, Gifu University Hospital, Gifu, Japan.
  • Maruyama D; Department of Hematology Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Machida R; JCOG Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan.
  • Ichinohe T; Department of Hematology and Oncology, Hiroshima University Research Institute for Radiation Biology and Medicine, Hiroshima, Japan.
  • Takayama N; Department of Hematology, Kyorin University School of Medicine, Tokyo, Japan.
  • Ohba R; Department of Clinical Oncology and Hematology, The Jikei University Daisan Hospital, Tokyo, Japan.
  • Ohmachi K; Department of Hematology/Oncology, Tokai University School of Medicine, Isehara, Japan.
  • Imaizumi Y; Department of Hematology, Nagasaki University Hospital, Nagasaki, Japan.
  • Tokunaga M; Department of Hematology, Imamura General Hospital, Kagoshima, Japan.
  • Katsuya H; Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan.
  • Yoshida I; Department of Hematologic Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan.
  • Sunami K; Department of Hematology, National Hospital Organization Okayama Medical Center, Okayama, Japan.
  • Kurosawa M; Department of Hematology, National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan.
  • Kubota N; Department of Hematology, Saitama Cancer Center, Saitama, Japan.
  • Morimoto H; Department of Hematology, University of Occupational and Environmental Health, Kitakyushu, Japan.
  • Kobayashi M; Department of Hematology and Oncology, Japanese Red Cross Nagoya Daini Hospital, Nagoya, Japan.
  • Kato H; Department of Hematology and Cell Therapy, Aichi Cancer Center, Nagoya, Japan.
  • Kameoka Y; Department of Hematology, Nephrology and Rheumatology, Akita University School of Medicine, Akita, Japan.
  • Kagami Y; Department of Hematology, Toyota Kosei Hospital, Toyota, Japan.
  • Kizaki M; Department of Hematology, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan.
  • Takeuchi K; First Department of Internal Medicine, Ehime University Hospital, Toon, Japan.
  • Munakata W; Department of Hematology, National Cancer Center Hospital, Tokyo, Japan.
  • Iida S; Department of Hematology and Oncology, Nagoya City University Hospital, Nagoya, Japan.
  • Nagai H; Department of Hematology, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
Jpn J Clin Oncol ; 51(7): 1059-1066, 2021 Jul 01.
Article em En | MEDLINE | ID: mdl-33959770
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Prednisolona / Bortezomib / Melfalan / Mieloma Múltiplo Tipo de estudo: Clinical_trials Limite: Aged / Female / Humans / Male Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Prednisolona / Bortezomib / Melfalan / Mieloma Múltiplo Tipo de estudo: Clinical_trials Limite: Aged / Female / Humans / Male Idioma: En Ano de publicação: 2021 Tipo de documento: Article